Other Events ·
Helus Pharma highlights HLP003 Phase 3 readout in Q4 2026 and HLP004 Phase 2 start in Q1 2027
CYBNCybin Inc.
Helus Pharma provided updates on its clinical pipeline during an investor presentation held on October 21, 2026. The company confirmed that topline data from the APPROACH Phase 3 study of HLP003 for major depressive disorder is on track for a Q4 2026 readout. Additionally, the HLP004 program for generalized anxiety disorder will initiate a Phase 2 monotherapy study in Q1 2027, enrolling approximately 144 participants. Helus Pharma operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.